Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aminoacridine→

Aminoacridine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
90-45-9
Molecular formula
C13H10N2
Molecular weight
194.23 g/mol
Drug class
Acridine derivativelocal antiseptic and nucleic-acid-interacting compound
Mechanism of action
Acridine compounds intercalate into nucleic acids and can interfere with microbial DNA replication and transcription. Specific clinical actions and toxicity depend on the exact aminoacridine derivative and formulation.
Indications / reported uses
  • Historical or regional topical antiseptic use for superficial wounds and local infections where a specific aminoacridine product is authorised; do not transfer this use to all acridine derivatives

Sources: NLM MeSH — Aminoacridines · PubMed — Aminoacridine antimicrobial pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aminoacridine Environmental Risk Assessment (ERA) (the Aminoacridine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.